Brightplext - Model IHC -Multiplex Cell Technology
HalioDx has developed advanced, reliable and customizable technologies to help immunotherapies developers in rationalizing and accelerating the pace of clinical programs from early phases to registration.
This customizable solution, a sequential chromogenic multiplex IHC, in addition with whole slide digital pathology analysis, allow to assess complex TME cells phenotyping on one FFPE tumor tissue section with up-to 7 biomarkers in order to provide valuable predictive and prognostic information, as well as insights on the underlying mechanisms of therapy response and resistance.
Our expertise in immuno-oncology and our IO Biomarkers Experts and scientists ensure a fast development of your project and provide you a dedicated support during all the different steps of the development.
HalioDx has a strong expertise in complex panels development, containing up-to 7 biomarkers each, for the identification of complex cell phenotypes.
Our image and data analysts ensure a standardized quantification of cell populations and the assessment of cells clustering as well as a proximity index.
